Anti Lipid Flashcards

(43 cards)

1
Q

_____ million Americans have elevated cholesterol. Dyslipidemias have been classified into 5 major subtypes. ____ causes half of all deaths in US. The incidence of CHD correlates with high levels of _____cholesterols and triacylglycerols and low levels of HDL cholesterol.

A

40; Coronary heart disease (CHD); LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What do the most common types of dyslipidemias involve

A
  1. elevated LDL (IIa) –> genetic component
  2. VLDL (IV)
  3. Both LDL and VLDL (IIb)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are risk factors for CHD

A
  1. cigarette smoking
  2. hypertension
  3. obesity
  4. family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what do lipid lowering therapies aim to do

A
  1. decrease carrier production
  2. increase degradation
  3. decrease absorption
  4. increase removal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

when is the patient borderline for total high cholesterol levels

A

220-240

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

when is patient borderline for LDL cholesterol

A

130-160

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

when is patient borderline for HDL cholesterol

A

35-60; want it greater than 60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the lipid lowering therapeutics

A
  1. HMG CoA Reductase Inhibitors (Statins)
  2. Fibrates
  3. Niacin (Vitamin B3)
  4. Cholesterol Absorption Inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the suffix of HMG CoA reductase inhibitors

A

“-statin”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Red rice yeast contains _____

A

lovastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which statin’s have adverse effects in the CNS

A
  1. Lovastatin

2. Simvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the indication for Atorvastatin

A
  1. Dyslipidemia

2. CVD Prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the mechanism of action of Atorvastatin

A
  1. Competitively inhibits HMG-CoA reeducates which is responsible for an early, rate limiting step in cholesterol biosynthesis.
  2. Increases hepatic LDL receptors, enhancing catabolism.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are common adverse effects of Atorvastatin

A
  1. nasopharyngitis

2. myalgia (muscle pain)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are skeletal AE of atorvastatin

A

myopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are hepatic AE of atorvastatin

A
  1. impaired function associated with elevated serum transaminase levels –> jaundice
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what are CNS AE of atorvastatin

A

amnesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are ocular AE of atorvastin

A
  1. dipolopia
  2. ptosis
  3. pseudo - CME
  4. blurred vision
  5. elevated IOP
  6. IOP hemorrhage
  7. cataracts
19
Q

What are drug interactions of atorvastatin

A

cyclosporine, erythromycin, azole antifungals cause myopathy exacerbation.

20
Q

What are contraindications of atorvastatin

A

azole antifungals

21
Q

What are the indication of fibrates

A
  1. hypertriglyceridemia

2. hypercholesterolemia

22
Q

when are fibrates prescribed

A

with statins or to statin intolerant patients; its a second line therapy, unless problems are severe and PCP decides to put them on both.

23
Q

what is the MOA of fenofibrate

A
  1. stimulates nuclear receptor PPAR which modulates transcription of insulin sensitive genes in liver, muscle and adipose tissue.
  2. enhances HDL production; inhibits triglyceride synthesis and stimulates catabolism of triglyceride rich lipoproteins.
24
Q

There is also an integral relationship between PPAR receptor and_______management and lipid level regulations in the body.

25
What are the endogenous ligands for PPARs?
free fatty acids and eicosanoids.
26
What are common AE of fenofibrate
1. headache 2. rhinitis 3. flu syndrome
27
What are serious AE of fenofibrate
1. hypersensitivity: SJS, TEN (toxic epidermal necrolysis) 2. Hepatitis, cirrhosis 3. CV: thromboembolism 4. Muscular: Mysotitis, myopathy, rhabdomyolysis
28
What are drug interactions of fenofibrate
1. Acyclovir, Amicoglycosides, cyclosporine, ganciclovir: cause impaired renal elimination 2. Impaired metabolism of Sulfonylureas (drugs used to treat diabetes --> pt can become hypoglycemic as a result of being on fenofibrate).
29
What is the indication of Niacin
1. hypertriglyceridemia 2. hypercholesterolemia 3. mixed dyslipidemia
30
What is the MOA of niacin
inhibits lypolysis in adipose tissue, resulting in reduced hepatic VLDL synthesis and production of LDLs in the plasma.
31
where does niacin act?
in the adipose tissue
32
what are common AE of niacin
1. headache 2. pseudo cystoid macular edema 3. flushing 4. pruritus 5. hyperpigmentaiton 6. jaundice 7. xeroderma 8. toxic amblyopia (impt!) 9. orthostatic hypotension
33
what are serious AE of niacin
1. hepatotoxicity | 2. arrhythmias
34
what are drug interactions of niacin
1. alpha blockers 2. beta blockers - both additive
35
When are you supposed to caution with use of niacin
1. diabetes (elevates blood sugar) | 2. surgery (anti platelet effects)
36
What is a cholesterol absorption inhibitor
Ezetimibe
37
what is the indication for ezetimibe
dyslipidemia
38
what is the MOA of ezetimibe
inhibits dietary and biliary cholesterol absorption at small intestine brush border.
39
what are common AE of ezetimibe
1. sinusitis 2. influenza 3. diarrhea
40
what are serious AE of ezetimibe
1. angioedema 2. anaphylaxis 3. hepatitis 4. thrombocytopenia
41
The most common thing to note among anti lipid drugs is that patient needs to have a healthy _____
liver
42
what are drug interactions of ezetimibe
cyclosporine; may increase levels of both drugs (the cyclosporine, and the ezetimibe)
43
when are you supposed to caution when using ezetimibe
hepatic impairment